Expert Ratings for Checkpoint Therapeutics
Portfolio Pulse from Benzinga Insights
Checkpoint Therapeutics (NASDAQ:CKPT) has received 4 analyst ratings in the last quarter, with 3 being bullish and 1 somewhat bullish. The average price target is $27.75, indicating a significant upside from the current price of $2.0. However, this average has decreased by 21.45% from the previous average price target of $35.33.
August 15, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Checkpoint Therapeutics has received positive analyst ratings, indicating potential upside. However, the decrease in the average price target could suggest less optimism.
Analyst ratings are a significant factor in stock performance. The bullish sentiment indicates a positive outlook for CKPT. However, the decrease in the average price target could suggest that analysts are less optimistic about the stock's future performance than they were previously.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100